N/A N=38 Non-Invasive Brain Stimulation and Substance Use
Substance Use Disorders
Primary: Change in Distress Tolerance (Mean Latency to Quit the PASAT-C) — 11.2; 9.8; 9.4 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=442 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Ovarian Cancer
Primary: Progression-free Survival by Independent Review Committee — 3.5; 3.6 months — p=0.6294
Phase 3 N=2,216 A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
Asthma
Primary: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 — 2.383; 2.387; 2.250; 2.176 litre (L) — p=<0.001
Phase 2 N=66 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Ulcerative Colitis · Digestive System Diseases · Colitis, Ulcerative
Primary: Number of Subjects With Treatment-related Adverse Events — 5; 7; 7; 14 Participants
N/A N=66 Neuromuscular Electrical Stimulation (NMES) for Improving Outcomes Following Total Knee Arthroplasty (TKA)
Arthropathy of Knee Joint
Primary: Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs) — 3.35; 15.95; -5.48 lbs
Phase 2 N=31 Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Adult Type Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma · Ovarian Sertoli-Leydig Cell Tumor
Primary: Probability of Complete Clinical Response — 3.2 Percentage of Participants
N/A N=101 Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea
Diarrhoea
Primary: Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1) — 21.30 hours
N/A N=16 Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation
Chronic Spinal Cord Injury · Neurogenic Bowel
Primary: Safety of Using TTNS at Home Daily as Indicated by Number of Adverse Events Recorded in Bladder Diary — 0 adverse events
Phase 4 N=114 Veterans Inpatient Insulin Study and Transition to Outpatient Therapy
Type 2 Diabetes Mellitus
Primary: For Transition From Inpatient to Outpatient Care, Evaluate Glycemic Control in Subjects Randomized to Receive 70/30 NPH/Regular Insulin or Aspart Analog 70/30 Mix Bid…
Phase 1 N=17 BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
HER2-positive Breast Cancer · Recurrent Breast Cancer · Stage IIIA Breast Cancer
Primary: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 — 0; 1; 0; 2 Participants
Phase 2 N=1,363 Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
Tetanus · Diphtheria · Pertussis
Primary: Number of Participants With Solicited Injections Site or Systemic Reactions Following Vaccination at Day 0: Aged 10-18 Years — 59; 51; 50; 49 Participants
N/A N=156 Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy.
Pregnancy Test
Primary: Number of Participants With Early Detection of Pregnancy — 142 Participants — p=0.025
Phase 4 N=11 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
Colitis, Ulcerative · Crohn's Disease
Primary: Concentration of Vedolizumab in Breast Milk at Predose on Day 1 — 0.1350; 0; 0.03161 ug/mL
N/A N=28 HYBRID: Hydrogen Breath Test in Lactose Digestion
Lactose Intolerance
Primary: Log of First Postprandial Peak Change of Hydrogen Concentration — 1.21; 1.10; 3.38; 3.59 log(ppm) — p=0.0801
N/A N=30 Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction — 10.6 percentage of LVEF